Therapeutic Response

EGFR Exon 20 (Insertion) status confers therapeutic sensitivity to Sunvozertinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Zegfrovy (sunvozertinib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to sunvozertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).